Trend in Clinical Trial Participation During COVID-19: A Secondary Analysis of the I-SPY COVID Clinical Trial

Autor: Philip Yang, MD, MSc, Neal W. Dickert, MD, PhD, Angela Haczku, MD, PhD, Christine Spainhour, RN, CCRC, Sara C. Auld, MD, MSc, the I-SPY COVID Consortium, Neil R. Aggarwal, MD, MHSc, Timothy Albertson, MD, Sara Auld, MD, Jeremy R. Beitler, MD, MPH, Paul Berger, DO, Ellen L. Burnham, MD, Carolyn S. Calfee, MD, MAS, Nathan Cobb, MD, Alessio Crippa, PhD, Andrea Discacciati, PhD, Martin Eklund, PhD, Laura Esserman, MD, MBA, D. Clark Files, MD, Eliot Friedman, MD, Sheetal Gandotra, MD, Kashif Khan, MD, Jonathan Koff, MD, Santhi Kumar, MD, Kathleen D. Liu, MD, PhD, Thomas R. Martin, MD, Michael A. Matthay, MD, Nuala J. Meyer, MD, Timothy Obermiller, MD, MS, Philip Robinson, MD, Derek Russell, MD, Karl Thomas, MD, Se Fum Wong, MD, Richard G. Wunderink, MD, Mark M. Wurfel, PhD, MD, Albert Yen, MD, Fady A. Youssef, MD, Anita Darmanian, MD, Amy L. Dzierba, PharmD, Ivan Garcia, RRT, Katarzyna Gosek, PharmD, Purnema Madahar, MD, MS, Aaron M. Mittel, MD, Justin Muir, PharmD, Amanda Roden, MD, John Schicchi, MD, Alexis L. Serra, MD, MPH, Romina Wahab, MD, Kevin W. Gibbs, MD, Leigha Landreth, RN, Mary LaRose, RN, Lisa Parks, RN, Adina Wynn, MPH, CCRP, Caroline A. G. Ittner, PhD, Nilam S. Mangalmurti, MD, John P. Reilly, MD, MS, Donna Harris, BSN, Abhishek Methukupally, MBBS, Siddharth Patel, MBBS, MPH, Lindsie Boerger, BA, John Kazianis, MD, Carrie Higgins, Jeff McKeehan, MS, Brian Daniel, RCP, RRT, Scott Fields, PharmD, James Hurst-Hopf, MS, Alejandra Jauregui, BA, Lamorna Brown Swigart, PhD, Daniel Belvins, CCRP, Catherine Nguyen, MD, Alexis Suarez, MS, Maged A. Tanios, MD, Farjad Sarafian, MD, Usman Shah, MD, Max Adelman, MD, MSc, Christina Creel-Bulos, MD, Joshua Detelich, MD, Gavin Harris, MD, Katherine Nugent, MD, Philip Yang, MD, Erin Hardy, Richart Harper, MD, Brian Morrissey, MD, Christian Sandrock, MD, MPH, G. R. Scott Budinger, MD, Helen K. Donnelly, RN, BSN, Benjamin D. Singer, MD, Ari Moskowitz, MD, Melissa Coleman, MD, Joseph Levitt, MD, Ruixiao Lu, PhD, Paul Henderson, PhD, Adam Asare, PhD, Imogene Dunn, PhD, Alejandro Botello Barragan

Publikováno v: Critical Care Explorations, Vol 5, Iss 6, p e0930 (2023)

OBJECTIVES:. To analyze the temporal trend in enrollment rates in a COVID-19 platform trial during the first three waves of the pandemic in the United States. DESIGN:. Secondary analysis of data from the I-SPY COVID randomized controlled trial (RCT).

Externí odkaz: https://doaj.org/article/7af4c25ca81249e2a0432daa16bb510e

Abstract P3-08-03: Dissecting the heterogeneity of metaplastic breast cancer: A morphological, immunohistochemical and genomic analysis of a large cohort

Autor: JC Liu, Lauren Kalinowski, QC Xu, M Bettington, Stephen B. Fox, JM Saunus, Puay Hoon Tan, E Kalaw, Kate J. Johnstone, Sunil R. Lakhani, Sandra A O'Toole, Katia Nones, A.E. McCart Reed, Kaltin Ferguson, Gary Tse, Irma Gresshoff, Colleen Niland, Peter T. Simpson, Rin Yamaguchi, David Papadimos, Stephen H. Kazakoff, LE Reid, Nick Waddell, Jamie R. Kutasovic, Gavin Harris, D Black, James Bennett, Andrew Scott Reid, Morgan R. Davidson, Rajadurai Pathmanathan, John V. Pearson, Malcolm Lim, Nirmala Pathmanathan, Ashwini Raghavendra

Publikováno v: Cancer Research. 79:P3-08

Although rare, Metaplastic Breast Carcinomas (MBC) account for significant global breast cancer mortality. This subgroup is extremely heterogeneous and by definition exhibits metaplastic change to squamous and/or mesenchymal elements, including but n

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e8f555c7b2b84c06eafb0a764a1282bd
https://doi.org/10.1158/1538-7445.sabcs18-p3-08-03

A Predictor of Early Disease Recurrence in Patients With Breast Cancer Using a Cell-free RNA and Protein Liquid Biopsy

Autor: Liam Williams, Cherie Blenkiron, Peter Tsai, Michael A. Black, Sunali Mehta, Cristin G. Print, Gavin Harris, Tamsin Robb, Annette Lasham, Nicholas Knowlton, Sandra Fitzgerald, Andrew N. Shelling

Publikováno v: Clinical breast cancer. 20(2)

Introduction Circulating biomarkers have been increasingly used in the clinical management of breast cancer. The present study evaluated whether RNAs and a protein present in the plasma of patients with breast cancer might have utility as prognostic

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::84e39f9fc87aef5cde3e5c3a7d1b0e3e
https://pubmed.ncbi.nlm.nih.gov/31607655

Phenotypic and molecular dissection of metaplastic breast cancer and the prognostic implications

Autor: Amy Ellen, McCart Reed, Emarene, Kalaw, Katia, Nones, Mark, Bettington, Malcolm, Lim, James, Bennett, Kate, Johnstone, Jamie Rose, Kutasovic, Jodi Marie, Saunus, Stephen, Kazakoff, Qinying, Xu, Scott, Wood, Oliver, Holmes, Conrad, Leonard, Lynne Estelle, Reid, Debra, Black, Colleen, Niland, Kaltin, Ferguson, Irma, Gresshoff, Ashwini, Raghavendra, Kate, Harvey, Caroline, Cooper, Cheng, Liu, Lauren, Kalinowski, Andrew Scott, Reid, Morgan, Davidson, John V, Pearson, Nirmala, Pathmanathan, Gary, Tse, David, Papadimos, Rajadurai, Pathmanathan, Gavin, Harris, Rin, Yamaguchi, Puay Hoon, Tan, Stephen B, Fox, Sandra A, O'Toole, Peter Thomas, Simpson, Nicola, Waddell, Sunil R, Lakhani

Publikováno v: Cancer Informatics

Metaplastic breast carcinoma (MBC) is relatively rare but accounts for a significant proportion of global breast cancer mortality. This group is extremely heterogeneous and by definition exhibits metaplastic change to squamous and/or mesenchymal elem

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::0ced8868122b2b4c55abfdb60aa1f492
https://pubmed.ncbi.nlm.nih.gov/31205411

Multimodal assessment of estrogen receptor mRNA profiles to quantify estrogen pathway activity in breast tumors

Autor: Michael A. Black, Kathryn J. Woad, Michael Findlay, Lance D. Miller, Nicole J. McCarthy, Anita Muthukaruppan, Cristin G. Print, Andrew N. Shelling, Gavin Harris, Annette Lasham, Cherie Blenkiron

Background Molecular markers have transformed our understanding of the heterogeneity of breast cancer and have allowed the identification of genomic profiles of estrogen receptor (ER)-α signaling. However, our understanding of the transcriptional pr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f459fd65e4113b6890d23cda7a79a887
http://eprints.nottingham.ac.uk/37806/